Iodixanol
- Atc Codes:V08AB09
- CAS Codes:92339-11-2
- PHARMGKB ID:92339-11-2
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Visipaque; Belgium: Visipaque; Bulgaria: Visipaque; Cyprus: Visipaque; Czech Republic: Visipaque; Denmark: Visipaque; Estonia: Visipaque; Finland: Visipaque; France: Visipaque; Germany: Visipaque; Greece: Visipaque; Hungary: Visipaque; Ireland: Visipaque; Italy: Visipaque; Latvia: Visipaque; Lithuania: Visipaque; Luxembourg: Visipaque; Malta: Visipaque; Poland: Visipaque; Romania: Visipaque; Slovakia: Visipaque; Slovenia: Visipaque; Spain: Visipaque; Sweden: Visipaque.
North America
Canada: Visipaque; USA: Visipaque.
Latin America
Argentina: Visipaque.
Asia
Japan: Visipaque.
Drug combinations
Chemistry
Iodixanol: C~35~H~44~I~6~N~6~O~15~. Mw: 1550.18. (1) 1,3-Benzenedicarboxamide, 5,5′-[(2-hydroxy-1,3-propanediyl)bis(acetylimino)]bis[N,N’-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-; (2) 5,5′-[(2-Hydroxytrimethylene)bis(acetylimino)]bis[N,N’-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide]. CAS-92339-11-2 (1990).
Pharmacologic Category
Diagnostic Agents; Imaging Agents; Iodinated Contrast Media. Radiological/Contrast Media. (ATC-Code: V08AB09).
Mechanism of action
Opacifies vessels in path of flow permitting radiographic imaging of internal structures.
Therapeutic use
Digital subtraction angiography, angiocardiography, peripheral arteriography, visceral arteriography, cerebral arteriography (intra-arterial). Contrasts enhanced computed tomography imaging, excretory urography, and peripheral venography (intravenous).
Pregnancy and lactiation implications
Fetal harm not observed in animal studies. There are no adequate, well-controlled studies in pregnant women. In general, iodinated contrast media agents are avoided during pregnancy unless essential for diagnosis. Not recommended in nursing women.
Unlabeled use
Contraindications
Hypersensitivity to iodixanol or any component of the formulation. Avoid intrathecal use. Prolonged fasting or laxative administration prior to iodixanol administration (pediatrics).
Warnings and precautions
May cause anaphylactoid reactions, delayed reactions, thromboembolic events. Caution in history of previous reaction to contrast dye or iodine, cardiovascular disease, hepatic impairment, multiple myeloma, known or suspected pheochromocytoma, renal impairment, sickle cell disease, thyroid disease, elderly patients with age-related renal impairment, pediatrics (increased risk of adverse effects, especially asthma, sensitivity to allergens or medications, heart disease, or renal dysfunction). For I.V. or intra-arterial use only. Glass syringes decrease likelihood of clotting of blood containing ioxilan.